Introduction The epidermal growth factor receptor inhibitor erlotinib is an approved treatment
for chemotherapy-refractory advanced non–small-cell lung cancer (NSCLC). Because …

7524 Background: Everolimus (RAD001) is an oral mTOR inhibitor that has been evaluated
as monotherapy in a phase II study of NSCLC patients (pts) previously treated with platinum …

Background Preclinical data suggest combining a mammalian target of rapamycin inhibitor
with erlotinib could provide synergistic antitumor effects in advanced non-small-cell lung …

Abstract Background and Rationale: Only 10% of patients with relapsed non–small cell lung
cancer (NSCLC) treated with chemotherapy or erlotinib have a partial response to treatment …

Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …

BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …

Purpose This study investigated whether sequential administration of erlotinib and
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …

Lung cancer is the leading cause of cancer deaths worldwide. Targeting the epidermal
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …

Introduction: This phase 2 study was conducted to determine the efficacy and safety of
erlotinib alone and with bortezomib in patients with non-small cell lung cancer (NSCLC) …

Treatment with third-generation chemotherapy agents improves survival and quality of life of
patients with non-small-cell lung cancer (NSCLC). Despite these favorable outcomes, most …